Published in Lancet on December 13, 2003
Ebola haemorrhagic fever. Lancet (2011) 8.28
Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature (2014) 6.94
Helminth infections: the great neglected tropical diseases. J Clin Invest (2008) 6.92
Effective post-exposure treatment of Ebola infection. PLoS Pathog (2007) 3.69
Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J Virol (2006) 3.50
Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc Natl Acad Sci U S A (2012) 3.35
Ebola hemorrhagic Fever: novel biomarker correlates of clinical outcome. J Infect Dis (2014) 2.84
Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog (2007) 2.64
Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol (2008) 2.58
Global suppression of the host antiviral response by Ebola- and Marburgviruses: increased antagonism of the type I interferon response is associated with enhanced virulence. J Virol (2006) 2.14
Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathog (2006) 2.01
Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb. Sci Rep (2013) 2.01
Ebola virus VP24 proteins inhibit the interaction of NPI-1 subfamily karyopherin alpha proteins with activated STAT1. J Virol (2007) 1.97
Evasion of interferon responses by Ebola and Marburg viruses. J Interferon Cytokine Res (2009) 1.91
Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates. Nature (2015) 1.76
Host response dynamics following lethal infection of rhesus macaques with Zaire ebolavirus. J Infect Dis (2011) 1.75
VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice. Antimicrob Agents Chemother (2006) 1.63
Homo-oligomerization facilitates the interferon-antagonist activity of the ebolavirus VP35 protein. Virology (2005) 1.63
Development and characterization of a mouse model for Marburg hemorrhagic fever. J Virol (2009) 1.62
Emerging targets and novel approaches to Ebola virus prophylaxis and treatment. BioDrugs (2013) 1.57
Blood coagulation, inflammation, and malaria. Microcirculation (2008) 1.54
Ebola GP-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infection. PLoS Negl Trop Dis (2012) 1.51
Animal models for Ebola and Marburg virus infections. Front Microbiol (2013) 1.51
Pathogenesis and immune response of Crimean-Congo hemorrhagic fever virus in a STAT-1 knockout mouse model. J Virol (2010) 1.49
Postexposure treatment of Marburg virus infection. Emerg Infect Dis (2010) 1.43
Forty-five years of Marburg virus research. Viruses (2012) 1.34
Current ebola vaccines. Expert Opin Biol Ther (2012) 1.30
Plasmodium falciparum-infected erythrocytes induce tissue factor expression in endothelial cells and support the assembly of multimolecular coagulation complexes. J Thromb Haemost (2006) 1.30
Managing potential laboratory exposure to ebola virus by using a patient biocontainment care unit. Emerg Infect Dis (2008) 1.30
Development of a model for marburgvirus based on severe-combined immunodeficiency mice. Virol J (2007) 1.30
Interferon-β therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever. J Infect Dis (2012) 1.27
The temporal program of peripheral blood gene expression in the response of nonhuman primates to Ebola hemorrhagic fever. Genome Biol (2007) 1.20
Evaluation of Different Strategies for Post-Exposure Treatment of Ebola Virus Infection in Rodents. J Bioterror Biodef (2011) 1.09
Mouse models for filovirus infections. Viruses (2012) 1.07
Simian hemorrhagic fever virus infection of rhesus macaques as a model of viral hemorrhagic fever: clinical characterization and risk factors for severe disease. Virology (2011) 1.07
Clinical aspects of Marburg hemorrhagic fever. Future Virol (2011) 1.06
Gastrointestinal and Hepatic Manifestations of Ebola Virus Infection. Dig Dis Sci (2015) 1.06
Thrombocytopenia in Dengue: Interrelationship between Virus and the Imbalance between Coagulation and Fibrinolysis and Inflammatory Mediators. Mediators Inflamm (2015) 1.05
A small nonhuman primate model for filovirus-induced disease. Virology (2011) 1.03
Multiple roles of the coagulation protease cascade during virus infection. Blood (2014) 0.94
Potential vaccines and post-exposure treatments for filovirus infections. Viruses (2012) 0.94
Human Ebola virus infection in West Africa: a review of available therapeutic agents that target different steps of the life cycle of Ebola virus. Infect Dis Poverty (2014) 0.94
Possible leap ahead in filovirus therapeutics. Cell Res (2014) 0.93
The role of antigen-presenting cells in filoviral hemorrhagic fever: gaps in current knowledge. Antiviral Res (2012) 0.92
Backs against the wall: novel and existing strategies used during the 2014-2015 Ebola virus outbreak. Clin Microbiol Rev (2015) 0.92
Transcriptional correlates of disease outcome in anticoagulant-treated non-human primates infected with ebolavirus. PLoS Negl Trop Dis (2014) 0.91
Medical research: Ebola therapy protects severely ill monkeys. Nature (2014) 0.91
State-of-the-Art Workshops on Medical Countermeasures Potentially Available for Human Use Following Accidental Exposures to Ebola Virus. J Infect Dis (2015) 0.90
Progress in the experimental therapy of severe arenaviral infections. Future Microbiol (2011) 0.90
Platelets and infection - an emerging role of platelets in viral infection. Front Immunol (2014) 0.88
"Filoviruses": a real pandemic threat? EMBO Mol Med (2009) 0.88
Ebola Virus Infections in Nonhuman Primates Are Temporally Influenced by Glycoprotein Poly-U Editing Site Populations in the Exposure Material. Viruses (2015) 0.87
A simian hemorrhagic fever virus isolate from persistently infected baboons efficiently induces hemorrhagic fever disease in Japanese macaques. Virology (2014) 0.86
Differential responses of disease-resistant and disease-susceptible primate macrophages and myeloid dendritic cells to simian hemorrhagic fever virus infection. J Virol (2013) 0.85
Filovirus emergence and vaccine development: a perspective for health care practitioners in travel medicine. Travel Med Infect Dis (2010) 0.84
The cyanobacterial lectin scytovirin displays potent in vitro and in vivo activity against Zaire Ebola virus. Antiviral Res (2014) 0.84
Protective role of cytotoxic T lymphocytes in filovirus hemorrhagic fever. J Biomed Biotechnol (2011) 0.84
Identification and pathological characterization of persistent asymptomatic Ebola virus infection in rhesus monkeys. Nat Microbiol (2017) 0.83
Ebola Virus Infection: Overview and Update on Prevention and Treatment. Infect Dis Ther (2015) 0.83
Myxomavirus-derived serpin prolongs survival and reduces inflammation and hemorrhage in an unrelated lethal mouse viral infection. Antimicrob Agents Chemother (2013) 0.83
Containing the threat--don't forget Ebola. PLoS Med (2004) 0.82
Circulating microRNA profiles of Ebola virus infection. Sci Rep (2016) 0.82
Viral hemorrhagic fevers: advancing the level of treatment. BMC Med (2012) 0.80
Are we any closer to combating Ebola infections? Lancet (2010) 0.79
Ebola Hemorrhagic Fever as a Public Health Emergency of International Concern; a Review Article. Emerg (Tehran) (2015) 0.79
Filoviruses: One of These Things is (not) Like the Other. Viruses (2015) 0.78
Endothelial cell dysfunction in viral hemorrhage and edema. Front Microbiol (2015) 0.78
Neglected filoviruses. FEMS Microbiol Rev (2016) 0.78
Aberrant coagulation causes a hyper-inflammatory response in severe influenza pneumonia. Cell Mol Immunol (2016) 0.78
Innate immunity, hemostasis and matrix remodeling: PTX3 as a link. Semin Immunol (2016) 0.77
Pre-symptomatic diagnosis and treatment of filovirus diseases. Front Microbiol (2015) 0.77
Evasion of the interferon-mediated antiviral response by filoviruses. Viruses (2010) 0.77
Post-exposure treatment of Ebola virus disease in guinea pigs using EBOTAb, an ovine antibody-based therapeutic. Sci Rep (2016) 0.77
Addressing the Complications of Ebola and Other Viral Hemorrhagic Fever Infections: Using Insights from Bacterial and Fungal Sepsis. PLoS Pathog (2015) 0.76
Chemically Modified Human Serum Albumin Potently Blocks Entry of Ebola Pseudoviruses and Viruslike Particles. Antimicrob Agents Chemother (2017) 0.75
Targeting clotting proteins in cancer therapy - progress and challenges. Thromb Res (2016) 0.75
Ebola hemorrhagic fever: genetic biomarkers and vaccine development. Genet Test Mol Biomarkers (2014) 0.75
Ebola Viral Disease in West Africa: A Threat to Global Health, Economy and Political Stability. J Public Health Africa (2016) 0.75
Updates in diagnosis and management of Ebola hemorrhagic fever. J Res Med Sci (2016) 0.75
Updates on Treatment of Ebola Virus Disease. Malays J Med Sci (2015) 0.75
Addressing Therapeutic Options for Ebola Virus Infection in Current and Future Outbreaks. Antimicrob Agents Chemother (2015) 0.75
Post-exposure treatment of non-human primates lethally infected with Ebola virus with EBOTAb, a purified ovine IgG product. Sci Rep (2017) 0.75
CHO cell production and sequence improvement in the 13C6FR1 anti-Ebola antibody. MAbs (2016) 0.75
Ebola: history, treatment, and lessons from a new emerging pathogen. Am J Physiol Lung Cell Mol Physiol (2014) 0.75
In vivo Ebola virus infection leads to a strong innate response in circulating immune cells. BMC Genomics (2016) 0.75
Tissue factor; from Morawitz to microparticles. Trans Am Clin Climatol Assoc (2007) 0.75
Molecular pathogenesis of viral hemorrhagic fever. Semin Immunopathol (2017) 0.75
Flex-nucleoside analogues - Novel therapeutics against filoviruses. Bioorg Med Chem Lett (2017) 0.75
Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med (2005) 6.77
Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA (2002) 6.59
Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature (2003) 6.35
The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J Virol (2003) 4.73
Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol (2003) 4.67
Exotic emerging viral diseases: progress and challenges. Nat Med (2004) 4.54
Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet (2010) 4.52
Ovarian tumor domain-containing viral proteases evade ubiquitin- and ISG15-dependent innate immune responses. Cell Host Microbe (2007) 4.14
Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations. Arch Virol (2010) 3.77
Effective post-exposure treatment of Ebola infection. PLoS Pathog (2007) 3.69
Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature (2004) 3.65
Bacillus anthracis lethal toxin induces TNF-alpha-independent hypoxia-mediated toxicity in mice. J Clin Invest (2003) 3.57
Interferon-γ links ultraviolet radiation to melanomagenesis in mice. Nature (2011) 3.56
Panmicrobial oligonucleotide array for diagnosis of infectious diseases. Emerg Infect Dis (2007) 3.51
Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia. MBio (2014) 3.49
Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Science (2013) 3.40
Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis (2003) 3.33
Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet (2006) 3.15
Overlapping motifs (PTAP and PPEY) within the Ebola virus VP40 protein function independently as late budding domains: involvement of host proteins TSG101 and VPS-4. J Virol (2003) 3.05
Interleukin 2 plays a central role in Th2 differentiation. Proc Natl Acad Sci U S A (2004) 2.98
Comprehensive panel of real-time TaqMan polymerase chain reaction assays for detection and absolute quantification of filoviruses, arenaviruses, and New World hantaviruses. Am J Trop Med Hyg (2010) 2.92
Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci U S A (2003) 2.82
Molecular Evidence of Sexual Transmission of Ebola Virus. N Engl J Med (2015) 2.71
Development of a new vaccine for the prevention of Lassa fever. PLoS Med (2005) 2.71
Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc Natl Acad Sci U S A (2010) 2.69
Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol (2003) 2.66
Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog (2007) 2.64
Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med (2006) 2.64
Evaluation of perceived threat differences posed by filovirus variants. Biosecur Bioterror (2011) 2.62
Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol (2008) 2.58
Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. J Infect Dis (2007) 2.44
A broad-spectrum antiviral targeting entry of enveloped viruses. Proc Natl Acad Sci U S A (2010) 2.41
Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. J Virol (2009) 2.41
Differential microRNA regulation of HLA-C expression and its association with HIV control. Nature (2011) 2.36
Virulence differences between monkeypox virus isolates from West Africa and the Congo basin. Virology (2005) 2.36
Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox. Proc Natl Acad Sci U S A (2004) 2.36
Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine (2008) 2.33
Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J Virol (2002) 2.31
Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis (2002) 2.26
Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and high-throughput antiviral drug screening. Virology (2005) 2.25
Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol (2005) 2.24
The chemotherapeutic agent DMXAA potently and specifically activates the TBK1-IRF-3 signaling axis. J Exp Med (2007) 2.23
Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference. J Infect Dis (2006) 2.19
Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species. PLoS Pathog (2010) 2.18
Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog (2008) 2.10
Marburg virus Angola infection of rhesus macaques: pathogenesis and treatment with recombinant nematode anticoagulant protein c2. J Infect Dis (2007) 2.09
Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily. Immunol Lett (2002) 2.06
Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses. J Virol (2011) 1.99
Growth factor independent-1 induced by IL-4 regulates Th2 cell proliferation. Immunity (2002) 1.99
Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther (2002) 1.96
Mouse susceptibility to anthrax lethal toxin is influenced by genetic factors in addition to those controlling macrophage sensitivity. Infect Immun (2004) 1.95
BCL-3 and NF-kappaB p50 attenuate lipopolysaccharide-induced inflammatory responses in macrophages. J Biol Chem (2004) 1.92
The host response to smallpox: analysis of the gene expression program in peripheral blood cells in a nonhuman primate model. Proc Natl Acad Sci U S A (2004) 1.85
Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine. J Virol (2006) 1.85
CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat Med (2011) 1.83
Local activation of the tissue factor-factor VIIa pathway in patients with pneumonia and the effect of inhibition of this pathway in murine pneumococcal pneumonia. Crit Care Med (2006) 1.82
SRT1720 improves survival and healthspan of obese mice. Sci Rep (2011) 1.81
Pulmonary inflammation and emphysema: role of the cytokines IL-18 and IL-13. Am J Respir Crit Care Med (2007) 1.79
Dendritic cells endocytose Bacillus anthracis spores: implications for anthrax pathogenesis. J Immunol (2005) 1.78